Bioreactors Market Analysis

Bioreactors Market Analysis

Bioreactors market from reusable bioreactors segment was over USD 6.5 billion in 2022. Healthcare companies and commercial drug manufacturers are heavily inclined towards reusable bioreactors as they offer high volume capacity and enhanced scalability. Even though manufacturing with reusable bioreactors such as stainless-steel bioprocessing systems is energy-intensive, in the long term, it is more cost-effective than single-use bioreactors. Since single-use systems require the replacement of disposable plastic components for each batch, the cumulative energy expenditure is 4 times greater than that of bioprocessing processes using multi-use systems.
 

Bioreactors market from yeast cells segment is expected to register over 4% CAGR through 2032. Yeasts are the most used microorganisms in the production of a broad spectrum of products and are subject to R&D initiatives exploiting potential applications. One of the prominent uses of yeast cells is in the manufacturing of protein-based and fermented products. Water management, pharmaceutical, and food and beverage manufacturing facilities are increasingly using flocculation bioreactors owing to their high productivity and cell density. These reactors are mainly used in manufacturing processes that require effective management of yeast flocculation.
 

Bioreactors market from gene therapy segment is estimated to exceed USD 1 billion by 2032. Rising incidences of genetic disorders are compelling further advancements in gene therapy. In recent years, private & public organizations have expedited R&D along with investments in biotechnology for drug discovery and development of novel therapeutics. Increasing applications of genetic engineering across green biotechnology will bolstering the genetic manipulation of plant cultures using sophisticated bioreactors.
 

Contract manufacturing organizations (CMOs) are estimated to hold more than a 12.5% share of the bioreactors market by 2032. CMOs are an emerging trend in the healthcare sector for outsourcing product development. These firms enable manufacturers to establish a solid presence across developing economies. CMOs also help organizations that lack a robust infrastructure and technical skills. Due to the growing need for outsourcing, CMOs are accelerating the adoption of bioreactors to achieve cost-efficiency, which will complement the industry progress.
 

Europe bioreactors market surpassed USD 3 billion in 2022. European countries have experienced dynamic growth in the adoption of next-generation bioreactors, particularly disposable bioreactors. The presence of many biotechnology companies in the region should offer lucrative scope for bioprocessing equipment manufacturers. Increasing efforts to develop and manufacture novel therapeutics, monoclonal antibodies, vaccines, and stem cells in bulk will further consolidate a promising demand for bioreactors across the region.
 

Furthermore, several start-ups across Europe are ramping up efforts to build innovative bioreactors. For instance, Switzerland’s Planetary & DAB.bio based in the Netherlands are designing bioreactors for fermentation. Meanwhile, UK-based start-ups such as Unicron Biotechnologies, Cellular Agriculture, and Animal Alternative Technologies are building bioreactors to develop new products from cell cultures.